Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia

被引:0
作者
Zhang, Lining [1 ,2 ,3 ]
Li, Jianping [1 ,2 ,3 ]
Liang, Weiru [1 ,2 ,3 ]
Zhang, Xiaoyu [1 ,2 ,3 ]
Chen, Shulian [1 ,2 ,3 ]
Shi, Yuanyuan [1 ,2 ,3 ]
Hao, Mengze [1 ,2 ,3 ]
Zhao, Xiaoli [1 ,2 ,3 ]
Gong, Ming [1 ,2 ,3 ]
Wei, Jialin [1 ,2 ,3 ]
He, Yi [1 ,2 ,3 ]
Jiang, Erlie [1 ,2 ,3 ]
Han, Mingzhe [1 ,2 ,3 ]
Zhang, Fengkui [1 ,2 ,3 ]
Feng, Sizhou [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosys, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
[3] Tianjin Inst Hlth Sci, Tianjin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
severe aplastic anemia; relapse; refractory; hematopoietic stem cell transplantation; immunosuppressive therapy; HIGH-DOSE CYCLOPHOSPHAMIDE; RABBIT ANTITHYMOCYTE GLOBULIN; BONE-MARROW-TRANSPLANTATION; EUROPEAN GROUP; ALTERNATIVE DONOR; SALVAGE THERAPY; GRAFT FAILURE; BLOOD; HORSE; CYCLOSPORINE;
D O I
10.3389/fimmu.2024.1425076
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The optimal treatment for patients with severe aplastic anemia (SAA) who fail an initial course of antithymocyte globulin (ATG) plus cyclosporine has not yet been established. We compared the effectiveness of allogeneic hematopoietic stem cell transplantation (allo-HSCT) (n = 36) with repeated immunosuppressive therapy (IST) (n = 33) for relapsed/refractory SAA between 2007 and 2022. In the IST group, patients were retreated with ATG (n = 16) or high-dose cyclophosphamide (n = 17). The overall response rate was 57.6% at 6 months and 60.6% at 12 months. In the allo-HSCT group, patients received a transplant from a matched sibling donor (n = 6), matched unrelated donor (n = 7), or haploidentical donor (n = 23). All patients achieved neutrophil engraftment, and there were no cases of primary graft failure. The cumulative incidences (CIs) of grades II-IV and III-IV acute graft-versus-host disease (GVHD) were 36.1% +/- 0.7% and 13.9% +/- 0.3% at day +100, respectively. The 4-year CI of chronic GVHD (cGVHD) was 36.2% +/- 0.7%, with moderate to severe cGVHD at 14.9% +/- 0.4%. Compared with IST, HSCT recipients showed much higher hematologic recovery rate at 3, 6, and 12 months (63.9%, 83.3%, and 86.1%, respectively, p < 0.001). The estimated 4-year overall survival (OS) (79.8% +/- 6.8% vs. 80.0% +/- 7.3%, p = 0.957) was similar; however, the failure-free survival (FFS) was significantly better in the HSCT group (79.8% +/- 6.8% vs. 56.6% +/- 8.8%, p = 0.049). Of note, children in the HSCT cohort were all alive without treatment failures, exhibiting superior OS (100% vs. 50.0% +/- 17.7%, p = 0.004) and FFS (100% vs. 50.0% +/- 17.7%, p = 0.004) than children in the IST cohort. Subgroup analysis revealed that younger patients (age <= 35 years), especially children, and those with refractory SAA benefited more from HSCT. Therefore, for these patients, salvage HSCT may be more preferable than a second course of IST.
引用
收藏
页数:10
相关论文
共 48 条
[1]   Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia [J].
Arcuri, Leonardo Javier ;
Nabhan, Samir Kanaan ;
Cunha, Renato ;
Nichele, Samantha ;
Feitosa Ribeiro, Andreza Alice ;
Fernandes, Juliana Folloni ;
Daudt, Liane Esteves ;
Melo Rodrigues, Ana Luiza ;
Arrais-Rodrigues, Celso ;
Seber, Adriana ;
Atta, Elias Hallack ;
Rodrigues de Oliveira, Jose Salvador ;
Moreira Funke, Vaneuza Araujo ;
Loth, Gisele ;
Darrigo Junior, Luiz Guilherme ;
Paz, Alessandra ;
Calixto, Rodolfo Froes ;
Gomes, Alessandra Araujo ;
Sa Araujo, Carlos Eduardo ;
Colturato, Vergilio ;
Simoes, Belinda Pinto ;
Hamerschlak, Nelson ;
Flowers, Mary Evelyn ;
Pasquini, Ricardo ;
Rocha, Vanderson ;
Bonfim, Carmem .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (12) :2311-2317
[2]  
Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3
[3]   How I treat acquired aplastic anemia [J].
Bacigalupo, Andrea .
BLOOD, 2017, 129 (11) :1428-1436
[4]   Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis [J].
Bacigalupo, Andrea ;
Socie, Gerard ;
Hamladji, Rose Marie ;
Aljurf, Mahmoud ;
Maschan, Alexei ;
Kyrcz-Krzemien, Slawomira ;
Chybicka, Alicja ;
Sengelov, Henrik ;
Unal, Ali ;
Beelen, Dietrich ;
Locasciulli, Anna ;
Dufour, Carlo ;
Passweg, Jakob R. ;
Oneto, Rosi ;
Signori, Alessio ;
Marsh, Judith C. W. .
HAEMATOLOGICA, 2015, 100 (05) :696-702
[5]   High-dose cyclophosphamide as salvage therapy for severe aplastic anemia [J].
Brodsky, RA ;
Chen, AR ;
Brodsky, I ;
Jones, RJ .
EXPERIMENTAL HEMATOLOGY, 2004, 32 (05) :435-440
[6]   Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia [J].
Brodsky, RA ;
Sensenbrenner, LL ;
Smith, BD ;
Dorr, D ;
Seaman, PJ ;
Lee, SM ;
Karp, JE ;
Brodsky, I ;
Jones, RJ .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (07) :477-483
[7]   High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up [J].
Brodsky, Robert A. ;
Chen, Allen R. ;
Dorr, Donna ;
Fuchs, Ephraim J. ;
Huff, Carol Ann ;
Luznik, Leo ;
Smith, B. Douglas ;
Matsui, William H. ;
Goodman, Steven N. ;
Ambinder, Richard F. ;
Jones, Richard J. .
BLOOD, 2010, 115 (11) :2136-2141
[8]  
CAMITTA BM, 1976, BLOOD, V48, P63
[9]  
CHAMPLIN RE, 1989, BLOOD, V73, P606
[10]   Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia [J].
Chen, Xin ;
Wei, Jialin ;
Huang, Yong ;
He, Yi ;
Yang, Donglin ;
Zhang, Rongli ;
Jiang, Erlie ;
Ma, Qiaoling ;
Zhai, Weihua ;
Yao, Jianfeng ;
Zhang, Guixin ;
Feng, Sizhou ;
Han, Mingzhe .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (01) :86-90